eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2022
vol. 17
 
Share:
Share:
Original paper

The usefulness of selected sequences of magnetic resonance imaging in a diagnostic model for Crohn’s disease

Barbara Tomicka-Szymanska
1
,
Mariusz Kaszubowski
2
,
Pawel J. Winklewski
3, 4
,
Joanna Pienkowska
1
,
Joanna Wypych
5
,
Maria Janiak
6
,
Arkadiusz Szarmach
1
,
Edyta Szurowska
1

1.
2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland
2.
Department of Economic Sciences, Faculty of Management and Economics, Gdansk University of Technology, Gdansk, Poland
3.
Department of Human Physiology, Medical University of Gdansk, Gdansk, Poland
4.
Department of Clinical Anatomy and Physiology, Pomeranian University of Slupsk, Slupsk, Poland
5.
Department of Gastroenterology, Surgery and Nutrition, Copernicus Hospital, Gdansk, Poland
6.
Department of Gastroenterology and Hepatology, Medical University of Gdansk, Gdansk, Poland
Gastroenterology Rev 2022; 17 (4): 316–320
Online publish date: 2022/12/07
Article file
- The usefulness.pdf  [0.14 MB]
Get citation
 
PlumX metrics:
 

Introduction

Crohn’s disease is a chronic inflammatory disorder that is relapsing in nature. Progression from inflammation to penetrating disease occurs following fibrosis. The aim of therapeutic strategies is to rapidly achieve and maintain remission, with the ultimate goal of improving the long-term prognosis [1]. In addition, emphasis is re-focused from the control of symptoms and normalisation of biochemical markers to the achievement of complete mucosal healing [2]. Importantly, the absence of clinical symptoms does not exclude active disease [3].

Conventional endoscopy with biopsy is the reference standard for diagnosing Crohn’s activity, and it remains key for the therapeutic management of Crohn’s disease [4]. However, it is an invasive technique, and its use beyond the colon and the final few centimetres of the ileum presents technical difficulties. Moreover, biopsy offers limited information about transmural and extra-enteric disease patterns. Colonic strictures represent an additional challenge associated with the biopsy procedure [5]. Due to its time-course, subjects suffering from Crohn’s disease often undergo multiple imaging exams to evaluate symptom recurrence. Magnetic resonance imaging (MRI) is increasingly recognised as a radiological modality of choice due to its lack of exposure to ionising radiation and established accuracy for detecting active disease [6]. In particular, the combination of MRI enterography (MRE) with diffusion-weighted imaging (DWI) of restricted areas may enhance the accuracy in determining Crohn’s disease activity compared to the use of either technique alone [7].

Visualisation of layered bowel wall enhancement (with visible dissections) can be obtained through dynamic examination following intravenous administration of a contrast medium [8, 9]. The apparent diffusion coefficient (ADC), a biophysical parameter representing the rate of diffusion, is also altered in inflamed regions [10, 11].

We hypothesised that, based on MRE layered bowel wall enhancement and ADC, measured in the affected parts of the intestine, it is possible to effectively differentiate between active and chronic phases of Crohn’s disease.

Aim

The aim of this study was to create a multidimensional diagnostic model that enables the differentiation of Crohn’s disease phases.

Material and methods

This study involved 125 patients: 55 women (aged 19 to 66 years) and 70 men (aged 12 to 67 years). All patients were referred for participation in this study based on clinical symptoms suggestive of Crohn’s disease. All patients in the study underwent MRE and ADC measurements for the first time.

The inclusion criteria were as follows: clinical suspicion of Crohn’s disease posed by a gastroenterologist based on clinical symptoms, no previous treatment for Crohn’s disease, and no contraindications for MRI examination or for use of an intravenous paramagnetic contrast agent. The exclusion criteria were as follows: lack of clinical suspicion of Crohn’s disease, diagnosed and previously treated for Crohn’s disease, morphological MRI features of bowel cancer, and contraindications to MRI examination.

The MRE examination was performed with a 3T Achieva scanner (Philips, Eindhoven, Netherlands). Patients were given 2 Scopolan tablets an hour before the test as well as a contrast solution consisting of 750 ml of water and 250 ml of mannitol to drink within 1 h. During the first phase of the study, the test was performed in the coronal and transverse planes. T1- and T2-weighted images were obtained in the TSE (Turbo Spin Echo), TFE (Turbo Field Echo), TFE/SPIR (Turbo Field Echo/Spectral Presaturation with Inversion Recovery), BTFE (Balanced Turbo Field Echo), and DWI sequences. During the second stage, an intravenous paramagnetic contrast agent was administered by a manual bolus through a cannula inserted into the cubital vein. The injection was terminated with 30 ml of saline. Following administration of the contrast agent, images were obtained using the THRIVE (T1-weighted High Resolution Isotropic Volume Examination) and TFE/SPIR sequences in the coronal and transverse planes. ProHance (Gadoteridol, Bracco Diagnostics, Milan, Italy) was used for all examinations.

Two radiologists analysed the acquired images for traits characteristic of changes during Crohn’s disease. The result was obtained by consensus.

The number of occupied regions was determined in patients who showed changes characteristic of Crohn’s disease. The considered regions included the jejunum, ileum, ileocecal region, caecum, colon, sigmoid colon, and rectum. A total of 125 occupied regions were found, which were then analysed. The following radiological features were analysed: thickness of the occupied section, length of the occupied section, number of lymph nodes present, layered bowel wall enhancement, total transitions on fat tissue, features of restricted diffusion in the DWI, and ADC values (Figures 14).

Figure 1

Non-fat saturation T2-weighted coronal image showing significant bowel wall thickening and luminal narrowing of the terminal ileum (arrowhead)

/f/fulltexts/PG/48407/PG-17-48407-g001_min.jpg
Figure 2

T1-weighted post-contrast coronal image showing stratification of the intestinal wall with trilaminar aspect of the bowel wall enhancement (arrowhead)

/f/fulltexts/PG/48407/PG-17-48407-g002_min.jpg
Figure 3

Diffusion-weighted (b = 800 s/mm2) axial image demonstrating high signal intensity due to restricted mural diffusion (arrowhead)

/f/fulltexts/PG/48407/PG-17-48407-g003_min.jpg
Figure 4

Apparent diffusion coefficient (value 1192) axial image demonstrating low signal intensity on the apparent diffusion map due to restricted mural diffusion of the terminal ileum (arrowhead)

/f/fulltexts/PG/48407/PG-17-48407-g004_min.jpg

Definitive diagnosis of Crohn’s disease was based on histological examination of material collected during ileocolonoscopy (96 patients), surgery with subsequent histopathological examination (17 patients), and capsule endoscopy (12 patients).

Statistical analysis

All raw data obtained from MR examination were analysed using Statistica 13.1 software (StatSoft, Tulsa, OK, USA).

Results

The final discrimination model was based on 2 variables: ADC and layered bowel wall enhancement. The stepwise analysis revealed that the best set of explanatory variables (Table I) was obtained by one of the simplest models (2-dimensional) among all considered. This model was statistically significant (p < 0.001), as well as each of its variables. All main assumptions were also fulfilled. The best variable for discriminating between active and chronic phases of Crohn’s disease was ADC (Wilks’ λ = 0.724, p < 0.001). The classification matrix (Table II) based on classification function (Table III) was able to identify the active form of Crohn’s disease with a probability of 93.06% and the chronic form with a probability of 75.57%, which gave a total predictive value of 85.60%.

Table I

Results of stepwise analysis for the best set of explanatory variables

LabelVariableWilks’ λ = 0.554, F (2,122) = 49.143, p < 0.001
Partial Wilks’FP-valueToler.1-Toler (R2)
AADC0.72446.586< 0.0010.9530.047
WLayered bowel wall enhancement0.91711.0470.0010.9530.047
Table II

Classification matrix for the chosen discrimination model

GroupClassification matrix
Correct (%)ActiveChronic
Active93.06675
Chronic75.471340
All85.608045
Table III

Coefficients of classification functions for the discrimination model

LabelVariableCoefficients
ActiveChronic
AADC0.0080.012
WLayered bowel wall enhancement4.7472.812
Constant–6.339-11.365
Classification functions
Active = –6.339 + 4.747W + 0.008A
Chronic = –11.365 + 2.812W + 0.012A

Discussion

Numerous studies have evaluated the use of MRE and DWI as potential markers of the grade and stage of Crohn’s disease [1214]. However, to the best of our knowledge, this is the first study performed on a large group of subjects to determine that the combination of MRE layered bowel wall enhancement and ADC value may yield a high predictive value, particularly with respect to discriminating the active form of Crohn’s disease from the chronic form.

A study by Koh et al. [8], which compared MRE with histopathological examination, showed diffuse bowel wall enhancement in 17 segments and a layered pattern in only 7 segments. The authors demonstrated that the intravenous administration of gadolinium results in significantly higher signal intensities in actively inflamed segments than those of bowel loops that appear normal. In this study, a ratio of 1.3 : 1 or more had a sensitivity of 68% and a specificity of 94% for active disease on a per-segment basis. Importantly, the authors analysed diffuse and layered bowel wall enhancement. Layered enhancement was seen only in patients with active phase of disease.

Bowel wall enhancement in active Crohn’s disease was also reported by Macarini et al. [15]. However, this study did not report direct correlations with histopathological changes, nor did it state how many segments were analysed. Research by Lasocki et al. [16] confirmed the high specificity and predictive value of MRE layered bowel enhancement in a group of 26 subjects with Crohn’s disease. Compared to previous studies using MRE layered bowel wall enhancement, our predictive model was based on a large group consisting of 125 subjects with Crohn’s disease.

Oto et al. [10] and Kiryu et al. [17] were the first to assess ADC as a radiological marker of active Crohn’s disease. In the study by Oto et al. [10], of the 19 inflamed segments, ADC detected 18 (grading score of 2 or 3), thus yielding a sensitivity of 94.7%. Kiryu et al. [17] analysed a total of 188 segments from 31 patients (17 with active Crohn’s disease), in which ADC showed high specificity (81.4%) and sensitivity (86.0%) as a marker of active Crohn’s disease. Restricted diffusion in inflamed bowel segments was later investigated by several other authors; however, these studies included a limited number of patients [1214].

The main advantage of DWI protocols is the avoidance of gadolinium-based contrast medium. Inflamed tissue restricts the diffusion of water, leading to a high DWI signal density, when the normal tissue signal is suppressed. Consequently, DWI with high b-values possess a spontaneous contrast that may highlight bowel segments with active disease in a similar manner to contrast-enhanced images. Therefore, DWI-based techniques are destined to replace classic contrast-enhanced MRE imaging techniques [18].

The strength of our model is its good ability to discriminate between active and chronic Crohn’s disease. It is sometimes challenging to differentiate fibrotic lesions and active inflammation on MRE images, particularly when these 2 pathologies coexist and the MRE features overlap. In active inflammation, the wall of the bowel exhibits restricted diffusion, with a low ADC value and high signal intensity on DWI, assessed using low and high b-values, respectively. Fibrotic tissue does not restrict diffusion, and it shows a higher ADC value and a signal that diminishes at high b-values.

Due to several shortcomings of DWI/ADC models, we propose a mixed diagnostic schedule that combines MRE and ADC. Using 2 parameters, namely MRE layered bowel wall enhancement and ADC, we were able to overcome the major shortcomings of both MRI techniques.

Importantly, our model does not require the establishment of cut-off values for ADC. The measured ADC (A) value was simply added to the equation, with active Crohn’s disease defined as –6.339 + 4.747 × W + 0.008 × A, while chronic Crohn’s disease was defined as –11.365 + 2.812 × W + 0.012 × A. The MRE layered bowel wall enhancement (W) was entered into the equation as “1” if at least one stratification of the intestinal wall was present, otherwise “0” was used. Therefore, our model eliminates a significant amount of subjectivity in the assessment of Crohn’s disease.

Conclusions

The use of classic MRE layered bowel wall enhancement and the DWI-based ADC metric allows the main shortcomings of both approaches to be eliminated. The current study included a large group of subjects, thereby increasing the reliability of the presented data.

Acknowledgments

Funding: The study was financed by the Medical University of Gdansk.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut 2017; 66: 2179-87.

2 

D’Haens G, Baert F, van Assche G, et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660-7.

3 

Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease? Aliment Pharmacol Ther 2002; 16: 857-67.

4 

Magro F, Gionchetti P, Eliakim R, et al.; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649-70.

5 

Li XH, Sun CH, Mao R, et al. Diffusion-weighted MRI enables to accurately grade inflammatory activity in patients of ileocolonic crohn’s disease: results from an observational study. Inflamm Bowel Dis 2017; 23: 244-53.

6 

Feng ST, Law MW, Huang B, et al. Radiation dose and cancer risk from pediatric CT examinations on 64-slice CT: a phantom study. Eur J Radiol 2010; 76: e19-23.

7 

Shenoy-Bhangle AS, Nimkin K, Aranson T, Gee MS. Value of diffusion-weighted imaging when added to magnetic resonance enterographic evaluation of Crohn disease in children. Pediatr Radiol 2016; 46: 34-42.

8 

Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol 2001; 177: 1325-32.

9 

Del Vescovo R, Santoni I, Caviglia R, et al. Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn’s disease. Abdom Imaging 2008; 33: 417-24.

10 

Oto A, Zhu F, Kulkarni K, et al. Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn’s disease. Acad Radiol 2009; 16: 597-603.

11 

Qi F, Jun S, Qi QY, et al. Utility of the diffusion-weighted imaging for activity evaluation in Crohn’s disease patients underwent magnetic resonance enterography. BMC Gastroenterol 2015; 15: 12.

12 

Dohan A, Taylor S, Hoeffel C, et al. Diffusion-weighted MRI in Crohn’s disease: Current status and recommendations. J Magn Reson Imaging 2016; 44: 1381-96.

13 

Imširović B, Zerem E, Efendić A, et al. Significance of diffusion weighted imaging (DWI) as an improving factor in contrast enhanced magnetic resonance imaging (MRI) enterography in evaluation of patients with Crohn’s disease. Med Glas 2018; 15: 145-51.

14 

Park SH. DWI at MR enterography for evaluating bowel inflammation in Crohn disease. AJR Am J Roentgenol 2016; 207: 40-8.

15 

Macarini L, Stoppino LP, Centola A, et al. Assessment of activity of Crohn’s disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score. Radiol Med 2013; 118: 181-95.

16 

Lasocki A, Pitman A, Williams R, et al. Relative efficacy of different MRI signs in diagnosing active Crohn’s disease, compared against a histological gold standard. J Med Imaging Radiat Oncol 2011; 55: 11-9.

17 

Kiryu S, Dodanuki K, Takao H, et al. Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn’s disease. J Magn Reson Imaging 2009; 29: 880-6.

18 

Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol 2014; 109: 89-98.

Copyright: © 2022 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.